Protonic Pump Inhibitors. A drug utilization study;Gli Inibitori della Pompa Protonica: Uno studio di drug utilization, con particolare riferimento all'appropriatezza del loro uso nella gastroprotezione

PharmacoEconomics - Italian Research Articles

Volumn 9, Issue 2, 2007, Pages 75-89

  Lucioni, Carlo ^a   Mazzi, S ^a   Cerra, C ^b   Fratino, P ^b  

^a Wolters Kluwer Health/ADIS International   (Italy)

^b ASL Pavia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; DRUG UTILIZATION; FEMALE; GASTRODUODENAL ULCER; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; RETROSPECTIVE STUDY; RISK;

EID: 34748895560     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320702     Document Type: Article

References (15)

1. Rentz AM, Battista C, Trudeau E, et al. Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature. Pharmacoeconomics 2001; 19: 349-63
2. Whitaker MJ. Consensus Guidelines for evaluating and treating patients with upper gastrointestinal symptoms in the primary care setting. Pharmacoeconomics 1998; 14 (Suppl. 2): 5-10
3. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-35
4. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Ass 2000; 40: 52-71
5. Champion G, Feng PH, Azuma T. NSAID-induced gastrointestinal damage: epidemiology, risk and prevention with an evaluation of the role of misoprostol. An Asian-Pacific perspective and consensus. Drugs 1997; 53: 6-19
6. Sigh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6
7. Legge 24 dicembre 1993, n. 537 e conseguenti provvedimenti applicativi del Ministero della Salute - terza revisione completa delle "Note"
8. Clark KW, Gray D. The Defined Daily Dose as a tool in pharmacoeconomics. Advantages and limitations. PharmacoEconomics 1995; 7: 280-3
9. Lucioni C, Mazzi S. Indicatori per il consumo dei farmaci: ruolo delle DDD e delle PDD. Pharmacoeconomics in infectious diseases, edizione italiana, 1996, settembre, 1-10
10. Lecomte T, Paris V. Consommation de pharmacie en Europe, 1992. Paris: CREDES, 1994
11. htto://www.whocc.no/
12. L'Informatore Farmaceutico. Milano: OEMF, 2006
13. Deambrosis P, Saramin C, Terrazzani G, et al. Dieci anni di utilizzo delle statine: adesione alla terapia e costi del trattamento farmacologico. Pharmacoeconomics- Italian Research Articles 2005; 7: 187-94
14. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60: 543-51
15. Lucioni C, Mazzi S, Cerra C, et al. Uno studio di drug utilization delle statine nella recente prassi terapeutica italiana. Pharmacoeconomics-Italian Research Articles 2006; 8: 3-17